Recipharm Expands Product Development Capabilities with New Facility

• Recipharm has opened a new Pilot Scale Development Centre in Germany, enhancing its product development and contract manufacturing capabilities.

• The facility features state-of-the-art equipment for GMP pilot-scale manufacturing of oral solid dose (OSD) formulations, supporting clinical supply, technology transfers, and small-batch production.

Recipharm, a global CDMO, has officially opened its new Pilot Scale Development Centre in Germany. The facility, first announced as an investment last year, is now fully operational with cutting-edge equipment aimed at advancing pharmaceutical product development and manufacturing.

The new centre is designed to ensure a seamless transition from product development to commercial manufacturing. It includes GMP pilot-scale rooms, a tablet press, a compression and compaction simulator, and advanced capsule filling equipment. These capabilities enhance Recipharm’s expertise in dry granulation, wet granulation, and material characterisation.

This investment addresses increasing industry demand for GMP pilot-scale capabilities. The facility supports clinical supply production, technology transfers, and small-scale commercial manufacturing, helping pharmaceutical companies accelerate development timelines.

The expansion also complements Recipharm’s broader product development offerings, which include API development, sterile fill-finish solutions, and analytical services. Looking ahead, Recipharm plans to open a Parenteral Development Centre in Bengaluru, India, in July 2025, focusing on sterile liquid formulations.

Dr. Uwe Hanenberg, Head of Product Development at Recipharm, commented: “With the addition of these new product development and pilot scale capabilities, alongside our ReciPredict Platform, we can now offer an even faster, cost-efficient and fully integrated solution for oral solids from clinical development to commercialisation.”